about
An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculatureTechnology evaluation: HspE7 (Stressgen).Listeria-based vaccines for cancer treatment.Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic abilityMultiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunizationLive, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment.Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.Development of a Listeria monocytogenes based vaccine against prostate cancer.The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication
P50
Q33773435-00786360-AA75-4DB1-9A52-79DC78530D18Q34415243-E41C0BD9-D045-427F-BAF8-7CF8549BD9D7Q36174279-CBC7F0B9-DC5A-4F3C-A787-713DE94EE456Q36296498-3FEC7052-D6D3-4651-9CCF-2E79D9BC35B7Q36504822-322BEA82-8584-4D2E-8EB3-5CAE47E586A1Q37388716-012F983A-19F0-461E-B85F-627A42D821C1Q37391175-3AD2C4E2-AEFA-400E-94D2-521054A729BEQ37843660-3FE7F879-70C1-41E6-981A-905A31D0D1F0Q39914585-7462B63F-059B-488D-93F9-508A60B1F771Q40005714-4A5D30A7-0811-478D-81E1-208FED9BBBA8Q40013300-3B30A19D-CA72-44CA-96C8-498BD96FF452Q40391633-01884112-4dbb-cbe7-62c3-ea6884953363Q81265217-8D716AB3-E922-439A-B142-DA4A267D7C2BQ81396898-BABCA6FD-A8DF-46D3-B01F-98CA503A6D40
P50
name
Paulo Cesar Maciag
@en
Paulo Cesar Maciag
@nl
type
label
Paulo Cesar Maciag
@en
Paulo Cesar Maciag
@nl
prefLabel
Paulo Cesar Maciag
@en
Paulo Cesar Maciag
@nl